10-Q: Spectral AI Reports Q3 Loss Amid R&D Shift, Secures Funding

Spectral AI reported a significant increase in net loss for Q3 2025, driven by reduced research and development activities as it nears FDA submission, while bolstering its liquidity with new debt and equity financing.

Summary

• Net loss for the three months ended September 30, 2025, increased to $3.55 million, up from $1.50 million in the same period of 2024.
• Year-to-date net loss for the nine months ended September 30, 2025, was $8.62 million, compared to $7.57 million for the same period in 2024.
• Research and development revenue decreased by 53.6% to $3.79 million in Q3 2025 and by 29.2% to $15.56 million year-to-date, primarily due to reduced activity as the company approached its FDA De Novo submission.
• Gross profit declined by 55.8% to $1.62 million in Q3 2025 and by 28.7% to $7.08 million year-to-date.
• Operating loss widened to $3.34 million in Q3 2025 from $0.89 million in Q3 2024.
• Cash balance increased to $10.50 million as of September 30, 2025, from $5.16 million at December 31, 2024.
• The company completed its FDA De Novo submission for the DeepView System in June 2025.
• Received UKCA marking for the DeepView System for burn indications in the United Kingdom in February 2024, with initial sales anticipated in the UK in 2025.
• Secured an initial $8.5 million draw-down from a $15.0 million Avenue Financing debt agreement in March 2025.
• Raised $2.7 million from an equity offering in March 2025.
• Subsequent to the quarter, raised $7.6 million in aggregate gross proceeds from a common stock and warrant offering in October 2025.
• Identified a new material weakness in internal controls related to a secondary revenue stream and an existing material weakness in financial statement close process controls.

Sentiment

Score: 4

Explanation: While the company made significant regulatory progress (FDA submission, UKCA approval) and secured substantial new funding, the financial performance for the quarter and year-to-date shows a worsening net loss and declining revenue. The identified material weaknesses in internal controls are also a notable concern. The positive developments are primarily strategic and future-oriented, while current financial results are negative.

Positives

• Successfully filed the De Novo application for the DeepView System with the FDA in June 2025, a critical step towards U.S. market authorization.
• Received UKCA marking for the DeepView System in February 2024, enabling anticipated initial sales in the UK in 2025.
• Secured significant funding, including an initial $8.5 million from the Avenue Financing and an additional $2.7 million from an equity raise in March 2025.
• Subsequent to the quarter, raised $7.6 million in aggregate gross proceeds from a common stock and warrant offering in October 2025, bolstering liquidity.
• Maintained substantial support from the U.S. government, with a BARDA contract providing up to $150.0 million in potential funding, and total potential BARDA support nearing $272.9 million.
• Completed enrollment for the pivotal clinical study with 267 patients by the end of 2024.
• Cash balance increased to $10.495 million as of September 30, 2025, from $5.157 million at December 31, 2024.

Negatives

• Net loss significantly increased to $3.55 million for Q3 2025, compared to $1.50 million for Q3 2024.
• Year-to-date net loss increased to $8.62 million for the nine months ended September 30, 2025, from $7.57 million in the prior year period.
• Research and development revenue decreased by 53.6% in Q3 2025 and 29.2% year-to-date, reflecting reduced activity.
• Operating loss widened substantially to $3.34 million in Q3 2025 from $0.89 million in Q3 2024.
• Accumulated deficit increased to $56.85 million as of September 30, 2025, from $48.23 million at December 31, 2024.
• Total liabilities increased to $23.50 million as of September 30, 2025, from $19.35 million at December 31, 2024.
• Identified a new material weakness in internal controls related to a secondary revenue stream and an existing material weakness in financial statement close process controls, indicating ineffective disclosure controls and procedures.

Risks

• Dependence on obtaining regulatory approval (FDA clearance) for products, which is a contingency for accessing the second tranche of Avenue Financing.
• High dependency on the continuation of existing U.S. governmental contract awards (BARDA, MTEC, DHA) and future governmental procurements for revenue.
• Risks common to development stage companies in the medical technology industry, including failure of preclinical studies and clinical trials, dependence on key personnel, and protection of proprietary technology.
• Potential negative impact on future revenue and gross margin percentages if lower pricing and incentives are needed to accelerate DeepView System adoption upon commercialization.
• Reliance on contract manufacturers and suppliers, which could lead to component shortages, delays, increased costs, and adverse impacts on cash flows and results of operations.
• Concentration of credit risk with one U.S. government agency representing 100% of accounts receivable and a majority of research and development revenue.
• Exposure to interest rate risk due to variable interest rates on borrowings (Prime plus 5.25% or 12.75%).
• Inflation risk could adversely affect gross margin and selling, general, and administrative expenses if costs continue to rise.
• Material weaknesses in internal controls over financial reporting, which could adversely affect the ability to record, process, summarize, and report financial information accurately.

Future Outlook

The company anticipates initial sales of the DeepView System in the UK to begin in 2025, following UKCA authorization. Upon receiving necessary regulatory market authorizations, the company intends to sell the DeepView System throughout the United States and the UK for its burn indication, supported by existing and future governmental contracts. The business model will transition to a SaaS offering and imaging device component. The company believes it has sufficient working capital to fund operations for at least one year beyond the release date of the condensed consolidated financial statements, contingent on future funding options and FDA clearance.

Management Comments

• Our DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characteristics invisible to the naked eye, at the initial time point of wound presentation.
• The DeepView System delivers a binary prediction on the wounds capacity to heal or not-heal by a specified time point in the future.
• Given our receipt of the UKCA authorization for our burn indication we anticipate initial sales in UK to begin in 2025.
• The sales channel for our burn indication will be supported by existing and future governmental contracts, primarily from agencies such as BARDA and the DHA.
• With the PBS BARDA Contract, the MTEC Agreement, and the Avenue Financing, the Company believes it has sufficient working capital to fund operations for at least one year beyond the release date of the condensed consolidated financial statements.
• Our management believes that the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in accordance with U.S. GAAP.

Industry Context

Spectral AI operates in the rapidly evolving AI-driven medical diagnostics sector, specifically targeting wound care with its DeepView System. The company's strategy of securing governmental contracts (BARDA, MTEC, DHA) for research, development, and initial deployment aligns with a common approach for novel medical technologies, especially those with potential applications in mass casualty events or military medicine. The pursuit of FDA De Novo classification for a Class II medical device positions it within a competitive landscape of diagnostic tools, where regulatory approval and clinical validation are paramount for market entry and adoption. The anticipated SaaS revenue model is consistent with broader trends in healthcare technology, emphasizing recurring revenue streams and software-as-a-service delivery.

Comparison to Industry Standards

• The company's reliance on government contracts for revenue is typical for early-stage medical device companies developing specialized technologies, particularly those with defense or public health applications, such as those funded by BARDA for countermeasure development.
• The pursuit of FDA De Novo classification for a Class II medical device is a standard regulatory pathway for novel, low-to-moderate risk devices without a predicate device, similar to other AI-powered diagnostic tools entering the U.S. market.
• The reported gross margins of 42.7% (Q3 2025) and 45.5% (YTD 2025) are within a reasonable range for medical technology companies, though they may fluctuate significantly as the company transitions from R&D contracts to commercial product sales.
• The substantial net losses and accumulated deficit are characteristic of a development-stage company investing heavily in R&D and clinical trials, similar to many biotech or med-tech startups prior to widespread commercialization.
• The identified material weaknesses in internal controls are a concern and indicate a need for robust financial infrastructure, which is a common challenge for companies scaling up or transitioning to public reporting, but must be addressed to meet public company standards.

Corporate Governance

Related Party Transactions

• Spectral IP, a wholly-owned subsidiary, received a $1.0 million investment from an affiliate of the largest stockholder in March 2024, structured as a note payable.
• The Spectral IP Note was amended in October 2024 to reduce interest, extend term, and include a conversion feature.
• The Spectral IP Note was fully converted into 540,996 shares of Common Stock in Q4 2024.
• Spectral IP entered into an intellectual property license agreement with the Company in May 2025.
• Spectral IP entered into a purchase agreement with Sauvegarder Investment Management, Inc. in November 2024 for reorganization, involving the issuance of Spectral IP common and preferred stock to Sauvegarder IM stockholders and forfeiture of most of the Company's Spectral IP shares.

Stakeholder Impact

• Shareholders: Dilution from recent and future equity raises, potential for increased share value upon FDA approval and commercialization, but also risk from ongoing losses and internal control weaknesses.
• Employees: Continued employment in R&D and operations, stock-based compensation plans, but also potential for shifts in focus as the company transitions to commercialization.
• Customers (Healthcare Providers): Potential for a new diagnostic tool (DeepView System) to improve burn wound assessment and treatment decisions, especially in emergency and trauma settings.
• Suppliers/Contract Manufacturers: Continued engagement for DeepView System components and production, but also risks of supply chain disruptions.
• Creditors (Avenue Capital Group): Secured debt financing with specific milestones and warrant coverage, indicating a structured investment with conditions for further tranches.
• Governmental Agencies (BARDA, MTEC, DHA): Continued partnership for research, development, and deployment of the DeepView System, supporting national preparedness and military health initiatives.

Next Steps

• Await FDA clearance of the DeepView System for Class II medical device designation.
• Initiate initial sales of the DeepView System in the UK in 2025.
• Pursue the second tranche of Avenue Financing, contingent on FDA clearance and a $7.0 million equity raise.
• Conduct health economic and outcome research studies to support broader clinical adoption of the DeepView System.
• Implement and test measures to remediate identified material weaknesses in internal controls over financial reporting.
• Continue research and development for a fully portable, handheld version of the DeepView System under DHA contract.
• Evaluate and strategically set pricing for SaaS and imaging device components per country and site-of-service.

Key Dates

Recommendation

The company is at a critical juncture, having completed its FDA De Novo submission and secured UKCA marking, which are significant positive steps towards commercialization. Substantial new funding also improves its liquidity position. However, the current financial performance shows worsening losses and declining revenue, typical of a pre-commercialization stage but still a concern. The identified material weaknesses in internal controls add a layer of operational risk. Investors should hold to monitor the outcome of the FDA review, the commencement of UK sales, and the successful remediation of internal control issues, as these events will be key determinants of future value. The recent capital raises provide a runway, but the path to profitability remains uncertain.

Keywords

Spectral AI, DeepView System, AI medical diagnostics, burn wound healing, FDA De Novo, UKCA marking, BARDA contract, medical technology, SaaS medical device, MDAI, quarterly report, financial results, liquidity, capital raise